Impact of Donor Type in Patients with AML Given Allogeneic Hematopoietic Cell Transplantation After Low-Dose TBI-Based Regimen

Frédéric Baron; Myriam Labopin; Annalisa Ruggeri; Jan J Cornelissen; Ellen Meijer; Henrik Sengeloev; Dietger Niederwieser; Marco R De Groot; Harry C Schouten; Noel Milpied; Didier Blaise; Bipin N Savani; Eliane Gluckman; Mohamad Mohty; Arnon Nagler

doi:10.1158/1078-0432.ccr-17-3622

Impact of Donor Type in Patients with AML Given Allogeneic Hematopoietic Cell Transplantation After Low-Dose TBI-Based Regimen

Frédéric Baron^*, Myriam Labopin, Annalisa Ruggeri, Jan J Cornelissen, Ellen Meijer, Henrik Sengeloev, Dietger Niederwieser, Marco R De Groot, Harry C Schouten, Noel Milpied, Didier Blaise, Bipin N Savani, Eliane Gluckman, Mohamad Mohty, Arnon Nagler

^*Corresponding author for this work

Department of Clinical Medicine

16 Citations (Scopus)

Abstract

Purpose: We assessed the impact of donor type in acute myeloid leukemia (AML) patients transplanted with 2 Gy total body irradiation (TBI)-based nonmyeloablative conditioning regimen.Patients and Methods: Data from 1,715 adult patients, with AML in CR1 or CR2 were included in this retrospective survey.Results: Donors consisted either of HLA-matched sibling donors (MSD, n = 701), 10/10 HLA-matched unrelated donors (MUD, n = 611), HLA-haploidentical donors (haplo, n = 112) or single or double umbilical cord bloods (CBT, n = 291). Chronic graft-versus-host disease (GVHD) was less frequent in CBT (28%) and in haplo (30%) patients than in MSD (50%) and MUD (51%) recipients (P < 0.001). Two-year incidence of relapse was 32%, 30%, 34%, and 34% in MSD, MUD, CBT and haplo patients, respectively (P = 0.7). Two-year overall (OS) and GVHD-free relapse-free survival (GRFS) were 59% and 29% in MSD patients, 56% and 39% in CBT recipients, 53% and 23% in MUD recipients, and 43% and 37% in haplo patients, respectively. In multivariate analyses, MUD patients had lower GRFS than MSD patients beyond day 100 (HR 1.3, P = 0.001) while CBT was associated with a better GRFS than MSD beyond day 100 (HR 0.6, P = 0.002).Conclusions: In this large cohort of AML patients transplanted following low-dose TBI-based conditioning, the relapse incidence was not affected by donor type suggesting that the intensity of GVL effects might be comparable with these four transplant approaches. Furthermore, CBT was associated with better GRFS beyond day 100 than MSD while the opposite was observed for MUD. Clin Cancer Res; 24(12); 2794-803. ©2018 AACR.

Original language	English
Journal	Clinical Cancer Research
Volume	24
Issue number	12
Pages (from-to)	2794-2803
Number of pages	10
ISSN	1078-0432
DOIs	https://doi.org/10.1158/1078-0432.ccr-17-3622
Publication status	Published - 15 Jun 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1158/1078-0432.ccr-17-3622

2794.full.pdfFinal published version, 576 KB

Cite this

Baron, F., Labopin, M., Ruggeri, A., Cornelissen, J. J., Meijer, E., Sengeloev, H., Niederwieser, D., De Groot, M. R., Schouten, H. C., Milpied, N., Blaise, D., Savani, B. N., Gluckman, E., Mohty, M., & Nagler, A. (2018). Impact of Donor Type in Patients with AML Given Allogeneic Hematopoietic Cell Transplantation After Low-Dose TBI-Based Regimen. Clinical Cancer Research, 24(12), 2794-2803. https://doi.org/10.1158/1078-0432.ccr-17-3622

Baron, F, Labopin, M, Ruggeri, A, Cornelissen, JJ, Meijer, E, Sengeloev, H, Niederwieser, D, De Groot, MR, Schouten, HC, Milpied, N, Blaise, D, Savani, BN, Gluckman, E, Mohty, M & Nagler, A 2018, 'Impact of Donor Type in Patients with AML Given Allogeneic Hematopoietic Cell Transplantation After Low-Dose TBI-Based Regimen', Clinical Cancer Research, vol. 24, no. 12, pp. 2794-2803. https://doi.org/10.1158/1078-0432.ccr-17-3622

@article{58b4daaab1f94be18d14010f8e0146f8,

title = "Impact of Donor Type in Patients with AML Given Allogeneic Hematopoietic Cell Transplantation After Low-Dose TBI-Based Regimen",

abstract = "Purpose: We assessed the impact of donor type in acute myeloid leukemia (AML) patients transplanted with 2 Gy total body irradiation (TBI)-based nonmyeloablative conditioning regimen.Patients and Methods: Data from 1,715 adult patients, with AML in CR1 or CR2 were included in this retrospective survey.Results: Donors consisted either of HLA-matched sibling donors (MSD, n = 701), 10/10 HLA-matched unrelated donors (MUD, n = 611), HLA-haploidentical donors (haplo, n = 112) or single or double umbilical cord bloods (CBT, n = 291). Chronic graft-versus-host disease (GVHD) was less frequent in CBT (28%) and in haplo (30%) patients than in MSD (50%) and MUD (51%) recipients (P < 0.001). Two-year incidence of relapse was 32%, 30%, 34%, and 34% in MSD, MUD, CBT and haplo patients, respectively (P = 0.7). Two-year overall (OS) and GVHD-free relapse-free survival (GRFS) were 59% and 29% in MSD patients, 56% and 39% in CBT recipients, 53% and 23% in MUD recipients, and 43% and 37% in haplo patients, respectively. In multivariate analyses, MUD patients had lower GRFS than MSD patients beyond day 100 (HR 1.3, P = 0.001) while CBT was associated with a better GRFS than MSD beyond day 100 (HR 0.6, P = 0.002).Conclusions: In this large cohort of AML patients transplanted following low-dose TBI-based conditioning, the relapse incidence was not affected by donor type suggesting that the intensity of GVL effects might be comparable with these four transplant approaches. Furthermore, CBT was associated with better GRFS beyond day 100 than MSD while the opposite was observed for MUD. Clin Cancer Res; 24(12); 2794-803. {\textcopyright}2018 AACR.",

author = "Fr{\'e}d{\'e}ric Baron and Myriam Labopin and Annalisa Ruggeri and Cornelissen, {Jan J} and Ellen Meijer and Henrik Sengeloev and Dietger Niederwieser and {De Groot}, {Marco R} and Schouten, {Harry C} and Noel Milpied and Didier Blaise and Savani, {Bipin N} and Eliane Gluckman and Mohamad Mohty and Arnon Nagler",

note = "{\textcopyright}2018 American Association for Cancer Research.",

year = "2018",

month = jun,

day = "15",

doi = "10.1158/1078-0432.ccr-17-3622",

language = "English",

volume = "24",

pages = "2794--2803",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research (A A C R)",

number = "12",

}

TY - JOUR

T1 - Impact of Donor Type in Patients with AML Given Allogeneic Hematopoietic Cell Transplantation After Low-Dose TBI-Based Regimen

AU - Baron, Frédéric

AU - Labopin, Myriam

AU - Ruggeri, Annalisa

AU - Cornelissen, Jan J

AU - Meijer, Ellen

AU - Sengeloev, Henrik

AU - Niederwieser, Dietger

AU - De Groot, Marco R

AU - Schouten, Harry C

AU - Milpied, Noel

AU - Blaise, Didier

AU - Savani, Bipin N

AU - Gluckman, Eliane

AU - Mohty, Mohamad

AU - Nagler, Arnon

PY - 2018/6/15

Y1 - 2018/6/15

N2 - Purpose: We assessed the impact of donor type in acute myeloid leukemia (AML) patients transplanted with 2 Gy total body irradiation (TBI)-based nonmyeloablative conditioning regimen.Patients and Methods: Data from 1,715 adult patients, with AML in CR1 or CR2 were included in this retrospective survey.Results: Donors consisted either of HLA-matched sibling donors (MSD, n = 701), 10/10 HLA-matched unrelated donors (MUD, n = 611), HLA-haploidentical donors (haplo, n = 112) or single or double umbilical cord bloods (CBT, n = 291). Chronic graft-versus-host disease (GVHD) was less frequent in CBT (28%) and in haplo (30%) patients than in MSD (50%) and MUD (51%) recipients (P < 0.001). Two-year incidence of relapse was 32%, 30%, 34%, and 34% in MSD, MUD, CBT and haplo patients, respectively (P = 0.7). Two-year overall (OS) and GVHD-free relapse-free survival (GRFS) were 59% and 29% in MSD patients, 56% and 39% in CBT recipients, 53% and 23% in MUD recipients, and 43% and 37% in haplo patients, respectively. In multivariate analyses, MUD patients had lower GRFS than MSD patients beyond day 100 (HR 1.3, P = 0.001) while CBT was associated with a better GRFS than MSD beyond day 100 (HR 0.6, P = 0.002).Conclusions: In this large cohort of AML patients transplanted following low-dose TBI-based conditioning, the relapse incidence was not affected by donor type suggesting that the intensity of GVL effects might be comparable with these four transplant approaches. Furthermore, CBT was associated with better GRFS beyond day 100 than MSD while the opposite was observed for MUD. Clin Cancer Res; 24(12); 2794-803. ©2018 AACR.

AB - Purpose: We assessed the impact of donor type in acute myeloid leukemia (AML) patients transplanted with 2 Gy total body irradiation (TBI)-based nonmyeloablative conditioning regimen.Patients and Methods: Data from 1,715 adult patients, with AML in CR1 or CR2 were included in this retrospective survey.Results: Donors consisted either of HLA-matched sibling donors (MSD, n = 701), 10/10 HLA-matched unrelated donors (MUD, n = 611), HLA-haploidentical donors (haplo, n = 112) or single or double umbilical cord bloods (CBT, n = 291). Chronic graft-versus-host disease (GVHD) was less frequent in CBT (28%) and in haplo (30%) patients than in MSD (50%) and MUD (51%) recipients (P < 0.001). Two-year incidence of relapse was 32%, 30%, 34%, and 34% in MSD, MUD, CBT and haplo patients, respectively (P = 0.7). Two-year overall (OS) and GVHD-free relapse-free survival (GRFS) were 59% and 29% in MSD patients, 56% and 39% in CBT recipients, 53% and 23% in MUD recipients, and 43% and 37% in haplo patients, respectively. In multivariate analyses, MUD patients had lower GRFS than MSD patients beyond day 100 (HR 1.3, P = 0.001) while CBT was associated with a better GRFS than MSD beyond day 100 (HR 0.6, P = 0.002).Conclusions: In this large cohort of AML patients transplanted following low-dose TBI-based conditioning, the relapse incidence was not affected by donor type suggesting that the intensity of GVL effects might be comparable with these four transplant approaches. Furthermore, CBT was associated with better GRFS beyond day 100 than MSD while the opposite was observed for MUD. Clin Cancer Res; 24(12); 2794-803. ©2018 AACR.

U2 - 10.1158/1078-0432.ccr-17-3622

DO - 10.1158/1078-0432.ccr-17-3622

M3 - Journal article

C2 - 29555662

SN - 1078-0432

VL - 24

SP - 2794

EP - 2803

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 12

ER -

Impact of Donor Type in Patients with AML Given Allogeneic Hematopoietic Cell Transplantation After Low-Dose TBI-Based Regimen

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this